SCHEMBL3767660

SCHEMBL3767660

COC(=O)C1CCCCCCC1=O

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.53
KDM4E B2RXH2 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MCL1 Q07820 1/20 0.47
KMT2A Q03164 1/20 0.45
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA4 P22748 2/20 0.42
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 2/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CA6 P23280 1/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7199566 1.00 MAPK1 (0.53) MAPK1KDM4EHSD17B10MCL1KMT2A
SCHEMBL6248372 1.00 MAPK1 (0.53) MAPK1KDM4EHSD17B10MCL1KMT2A
SCHEMBL1615850 1.00 MAPK1 (0.53) MAPK1KDM4EHSD17B10MCL1KMT2A
SCHEMBL27922653 1.00 MAPK1 (0.53) MAPK1KDM4EHSD17B10MCL1KMT2A
SCHEMBL3171 0.98 MAPK1 (0.54) MAPK1KDM4EHSD17B10MCL1KMT2A
SCHEMBL20303983 0.98 MAPK1 (0.54) MAPK1KDM4EHSD17B10MCL1KMT2A
SCHEMBL7305358 0.98 MAPK1 (0.54) MAPK1KDM4EHSD17B10MCL1KMT2A
SCHEMBL25061 0.92 MAPK1 (0.47) MAPK1KDM4EHSD17B10MCL1CA1
SCHEMBL31276435 0.92 MAPK1 (0.47) MAPK1KDM4EHSD17B10MCL1CA1
SCHEMBL374935 0.92 MAPK1 (0.47) MAPK1KDM4EHSD17B10MCL1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400792-A1 CURABLE (METH)ACRYLATE COMPOSITIONS HENKEL AG & CO KGAA (DE) 2024-12-05 US claimed
US-20240400784-A1 Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition LG CHEM, LTD. (KR) 2024-12-05 US claimed
US-20240392094-A1 Method for Screening Solvent for Polyvinyl Chloride Extraction, Recycling Method for Waste Material, and Recycled Polyvinyl Chloride and Composition LG CHEM, LTD. (KR) 2024-11-28 US claimed
CN-118355086-A Curable (meth) acrylate composition 汉高股份有限及两合公司 2024-07-16 CN claimed
CN-117897440-A Method for screening solvent for extraction of polyvinyl chloride, method for recycling waste material, recycled polyvinyl chloride and composition 株式会社LG化学 2024-04-16 CN claimed
CN-117897439-A Method for screening solvent for extraction of polyvinyl chloride, method for recovering waste material, and recovered polyvinyl chloride and composition 株式会社LG化学 2024-04-16 CN claimed
WO-2023104819-A1 CURABLE (METH) ACRYLATE COMPOSITIONS Henkel IP & Holding GmbH (DE) 2023-06-15 WO claimed
WO-2023033605-A1 METHOD FOR SCREENING SOLVENT FOR EXTRACTING POLYVINYL CHLORIDE, METHOD FOR RECYCLING WASTE, RECYCLED POLYVINYL CHLORIDE, AND COMPOSITION 주식회사 엘지화학 2023-03-09 WO claimed
WO-2023033601-A1 METHOD FOR SCREENING SOLVENT FOR POLYVINYL CHLORIDE EXTRACTION, RECYCLING METHOD FOR WASTE MATERIAL, AND RECYCLED POLYVINYL CHLORIDE AND COMPOSITION 주식회사 엘지화학 2023-03-09 WO claimed
US-20240400784-A1 Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition LG CHEM, LTD. (KR) 2024-12-05 US disclosed
US-20240400792-A1 CURABLE (METH)ACRYLATE COMPOSITIONS HENKEL AG & CO KGAA (DE) 2024-12-05 US disclosed
US-20240392094-A1 Method for Screening Solvent for Polyvinyl Chloride Extraction, Recycling Method for Waste Material, and Recycled Polyvinyl Chloride and Composition LG CHEM, LTD. (KR) 2024-11-28 US disclosed
US-20240342295-A1 FUNCTIONALISATION OF CARBOXYMETHYLCELLULOSE THE UNIVERSITY OF MANCHESTER (GB) 2024-10-17 US disclosed
CN-118355086-A Curable (meth) acrylate composition 汉高股份有限及两合公司 2024-07-16 CN disclosed
US-6921776-B1 Compound STERIX LIMITED (GB) 2005-07-26 US disclosed
US-20050154050-A1 Compound REED MICHAEL J (GB) 2005-07-14 US disclosed
EP-0610439-B1 PYRIMIDOCYCLOALKANES AS ANGIOTENSIN II ANTAGONISTS AMERICAN HOME PROD (US) 1999-12-15 EP disclosed
EP-0610439-A1 PYRIMIDOCYCLOALKANES AS ANGIOTENSIN II ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1994-08-17 EP disclosed
US-5234936-A Treating hypertension, congestive heart failure, hyperlipidemia and hypercholesterolemia AMERICAN HOME PRODUCTS CORPORATION (US) 1993-08-10 US disclosed
WO-1993008171-A1 PYRIMIDOCYCLOALKANES AS ANGIOTENSIN II ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1993-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154050-A1 Compound HSD17B11, NR5A1, CYP17A1 MAPK1 4081/4885KDM4E 1129/4885HSD17B10 24/4885
US-20240342295-A1 FUNCTIONALISATION OF CARBOXYMETHYLCELLULOSE CHRM2, CMBL, H1-0 MAPK1 1745/4885KDM4E 987/4885HSD17B10 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.